Mind Medicine (Mind Medicine) Pre-Tax Income : $-125.32 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mind Medicine Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Mind Medicine's pretax income for the three months ended in Mar. 2024 was $-54.40 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-125.32 Mil. Mind Medicine's pretax margin was %.

Mind Medicine Pre-Tax Income Historical Data

The historical data trend for Mind Medicine's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Pre-Tax Income Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-33.94

-94.19

-56.80

-95.73

Mind Medicine Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial													-24.82	-29.13	-17.92	-23.86	-54.40

Competitive Comparison of Mind Medicine's Pre-Tax Income

For the Biotechnology subindustry, Mind Medicine's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mind Medicine's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Pre-Tax Income falls into.

Mind Medicine Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Mind Medicine's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-93.866	+	-6.53	+	0	+	0	+	4.664
	=	-95.73

Mind Medicine's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-22.204	+	-33.418	+	-0.434	+	1.656	+	0
	=	-54.40

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-125.32 Mil.

Mind Medicine (OTCPK:MMCWF) Pre-Tax Income Explanation

Mind Medicine's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-54.4	/	0
	=	%

Mind Medicine Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine (Mind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

MNMD:USA MMQ:Germany MMED:Canada

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.